Real-time Quotes | Nasdaq Last Sale

After Hours: 6.62 -0.1 -1.49% 13:16 11/27 EST
Corp Actions
Here is What Hedge Funds Think About Bellerophon Therapeutics, Inc. (BLPH)
Although the masses and most of the financial media blame hedge funds for their exorbitant fee structure and disappointing performance, these investors have proved to have great stock picking abilities over the years (that’s why their assets under management continue to swell). We believe hedge fund sentiment should serve as a crucial tool of an […]
Insider Monkey · 1d ago
Mid-Afternoon Market Update: Dow Surges 250 Points; Bellerophon Therapeutics Shares Slide
Toward the end of trading Monday, the Dow traded up 0.89% to 29,522.86 while the NASDAQ rose 0.08% to 11,864.80. The S&P also rose, gaining 0.37% to 3,570.63.
Benzinga · 6d ago
AHT, FCEL, AIM and MARA among midday movers
Gainers: DPW Holdings (DPW) +179%.Ideanomics (IDEX) +65%.Fuel Tech (FTEK) +61%.Greenland Technologies (GTEC) +52%.Kaixin Auto (KXIN) +52%.FuelCell Energy (FCEL) +45%.CIIG Merger (CIIC) +37%.Graybug Vision (GRAY) +36%.Beam Global (BEEM) +35%.Marathon Patent (MARA) +33%.Losers: Bellerophon Therapeutics
Seekingalpha · 6d ago
Mid-Day Market Update: Nasdaq Edges Lower; DPW Shares Spike Higher
Midway through trading Monday, the Dow traded up 0.53% to 29,417.20 while the NASDAQ fell 0.19% to 11,832.26. The S&P also rose, gaining 0.07% to 3,559.94.
Benzinga · 6d ago
Medigus, 180 Life Sciences leads healthcare gainers; Bellerophon Therapeutics, BioLineRx among major losers
Gainers: Medigus (MDGS) +36%, 180 Life Sciences (ATNF) +35%, Graybug Vision (GRAY) +23%, Trinity Biotech (TRIB) +18%, Accuray (ARAY) +14%.Losers: Bellerophon Therapeutics (BLPH) -18%, BioLineRx (BLRX) -13%, AIM ImmunoTech (AIM) -11%, iBio (IBIO) -10%, OptiNose (OPTN) -10%.
Seekingalpha · 6d ago
Mid-Morning Market Update: Markets Open Higher; AstraZeneca Covid-19 Vaccine Shows Up To 90% Efficacy In Late-Stage Trials
Following the market opening Monday, the Dow traded up 0.61% to 29,442.35 while the NASDAQ rose 0.12% to 11,868.79. The S&P also rose, gaining 0.38% to 3,571.09.
Benzinga · 6d ago
Bellerophon Therapeutics Puts COViNOX Study Of INOpulse For COVID-19 On Clinical Hold
WARREN, N.J., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing
Benzinga · 6d ago
Bellerophon Therapeutics Announces Results of Interim Analysis of Phase 3 COViNOX Study of INOpulse® for the Treatment of COVID-19
WARREN, N.J., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and infectious diseases, today announced that the independent Data Monitoring Committee (DMC) has completed its pre-specified interim analysis from the first 100 patients randomized in the Phase 3 COViNOX study of INOpulse® for the treatment of COVID-19. The interim analysis, as requested by the U.S. Food and Drug Administration, was limited to the evaluation of safety and a single efficacy endpoint of respiratory failure or death (RFD).“Based on the recommendation of the DMC, we have put the COViNOX study on clinical hold. To date, we have recruited close to 200 patients, of which 100 were included in the interim analysis. Of note, the interim analysis included 10 RFD events, representing a small sample size for evaluation of the RFD endpoint. We intend to complete the study procedures for the remaining patients and evaluate the full data set, which will include additional clinically important endpoints, such as change in clinical status and duration of hospitalization, in order to assess potential next steps in our COVID-19 program,” said Fabian Tenenbaum, Chief Executive Officer of Bellerophon Therapeutics.“We continue to be enthusiastic about our lead program in fibrotic interstitial lung disease (fILD) and other pulmonary hypertension (PH) programs, which leverage years of experience with inhaled nitric oxide as a targeted and potent vasodilator to address the underlying vascular resistance and improve hemodynamics, ventilation/perfusion mismatch, quality of life, and exercise capacity in these patients. These indications represent significant unmet medical needs for which there are currently no approved therapies. Importantly, following the positive results from our Phase 2 studies, we expect to enroll the first patient in our Phase 3 REBUILD study in fILD shortly, and our ongoing Phase 2b trial in PH associated with sarcoidosis is progressing well, with top-line results anticipated around the end of 2020,” concluded Mr. Tenenbaum.About Bellerophon Bellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative therapies that address significant unmet medical needs in the treatment of cardiopulmonary and infectious diseases. The Company is currently developing multiple product candidates under its INOpulse® program, a proprietary pulsatile nitric oxide delivery system. For more information, please visit Statements Any statements in this press release about Bellerophon’s future expectations, plans and prospects, including statements about the clinical development of its product candidates, regulatory actions with respect to the Company’s clinical trials and expectations regarding the sufficiency of the Company’s cash balance to fund clinical trials, operating expenses and capital expenditures, and other statements containing the words “anticipate,” “believe,” “continue,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: risks and uncertainties relating to INOpulse® not proving to be an effective treatment for COVID-19 or approved for marketing by the FDA, the uncertainties inherent in the initiation of future clinical trials, availability and timing of data from ongoing and future clinical trials and the results of such trials, whether preliminary or interim results from a clinical trial will be predictive of the final results of that trial or whether results of early clinical trials will be indicative of the results of later clinical trials, expectations for regulatory approvals, the FDA’s substantial discretion in the approval process, availability of funding sufficient for our foreseeable and unforeseeable operating expenses and capital expenditure requirements and other factors discussed in the “Risk Factors” section of the Company’s most recent Annual Report on Form 10-K and in subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements included in this press release represent Bellerophon’s views only as of the date of this release and should not be relied upon as representing the Company’s views as of any subsequent date. The Company specifically disclaims any obligation to update any forward-looking statements included in this press release.Contacts At W2O Group:At LifeSci Advisors: Julie NormartBrian Ritchie (559) 974-3245(212) 915-2578
GlobeNewswire · 6d ago
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of BLPH. Analyze the recent business situations of Bellerophon through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts


Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average BLPH stock price target is 26.50 with a high estimate of 35.00 and a low estimate of 19.00.
Institutional Holdings
Institutions: 64
Institutional Holdings: 6.91M
% Owned: 72.74%
Shares Outstanding: 9.50M
Sold Out
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Biotechnology & Medical Research
Pharmaceuticals & Medical Research
Key Executives
Jonathan Peacock
Chief Executive Officer/Chief Financial Officer/Director
Fabian Tenenbaum
Chief Financial Officer/Secretary
Assaf Korner
Vice President - Operations
Parag Shah
Vice President
Martin Dekker
Vice President - Administration
Amy Edmonds
Wassim Fares
Peter Fernandes
Ted Wang
Independent Director
Naseem Amin
Independent Director
Matthew Bennett
Independent Director
Scott Bruder
Independent Director
Mary Cloyd
Independent Director
Andre Moura
Independent Director
Crispin Teufel
Independent Director
Theodore Wang
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About BLPH
Bellerophon Therapeutics, Inc. is a clinical-stage therapeutics company. The Company is focused on developing products at the intersection of drugs and devices that address medical needs in the treatment of cardiopulmonary diseases. The Company is focused on the development of its nitric oxide therapy for patients with pulmonary hypertension (PH), using its delivery system, INOpulse, with pulmonary arterial hypertension (PAH) as the lead indication. The Company's INOpulse device has a mechanism that delivers brief, targeted pulses of nitric oxide timed to occur at the beginning of a breath for delivery to the alveoli of the lungs, which minimizes the amount of drug required for treatment. INOpulse is designed to be compatible with many long-term oxygen therapy (LTOT) systems via nasal cannula delivery.
Hot Stocks

Webull offers kinds of Bellerophon Therapeutics Inc stock information, including NASDAQ:BLPH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BLPH stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BLPH stock methods without spending real money on the virtual paper trading platform.